Literature DB >> 31665810

Cyclic AMP-dependent positive feedback signaling pathways in the cortex contributes to visceral pain.

Shui-Bing Liu1,2,3, Xin-Shang Wang1,2, Jiao Yue1,2, Le Yang1,2, Xu-Hui Li4, Li-Ning Hu1,2, Jing-Shan Lu4, Qian Song4, Kun Zhang1,2, Qi Yang1,2, Ming-Ming Zhang5, Matteo Bernabucci3, Ming-Gao Zhao1,2, Min Zhuo3,4.   

Abstract

Cortical areas including the anterior cingulate cortex (ACC) play critical roles in different types of chronic pain. Most of previous studies focus on the sensory inputs from somatic areas, and less information about plastic changes in the cortex for visceral pain. In this study, chronic visceral pain animal model was established by injection with zymosan into the colon of adult male C57/BL6 mice. Whole cell patch-clamp recording, behavioral tests, western blot, and Cannulation and ACC microinjection were employed to explore the role of adenylyl cyclase 1 (AC1) in the ACC of C57/BL6 and AC1 knock out mice. Integrative approaches were used to investigate possible changes of neuronal AC1 in the ACC after the injury. We found that AC1, a key enzyme for pain-related cortical plasticity, was significantly increased in the ACC in an animal model of irritable bowel syndrome. Inhibiting AC1 activity by a selective AC1 inhibitor NB001 significantly reduced the up-regulation of AC1 protein in the ACC. Furthermore, we found that AC1 is required for NMDA GluN2B receptor up-regulation and increases of NMDA receptor-mediated currents. These results suggest that AC1 may form a positive regulation in the cortex during chronic visceral pain. Our findings demonstrate that the up-regulation of AC1 protein in the cortex may underlie the pathology of chronic visceral pain; and inhibiting AC1 activity may be beneficial for the treatment of visceral pain.
© 2019 International Society for Neurochemistry.

Entities:  

Keywords:  AC1; ACC; GluN2B; visceral pain

Mesh:

Substances:

Year:  2020        PMID: 31665810     DOI: 10.1111/jnc.14903

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Human safety study of a selective neuronal adenylate cyclase 1 inhibitor NB001 which relieves the neuropathic pain and blocks ACC in adult mice.

Authors:  Weicong Wang; Qi-Yu Chen; Pengpeng Zhao; Jingbo Zhong; Yan Wang; Xiaorong Li; Min Zhuo; Xia Chen
Journal:  Mol Pain       Date:  2022-04       Impact factor: 3.370

2.  Inhibition of calcium-stimulated adenylyl cyclase subtype 1 (AC1) for the treatment of neuropathic and inflammatory pain in adult female mice.

Authors:  Zhaoxiang Zhou; Wantong Shi; Kexin Fan; Man Xue; Sibo Zhou; Qi-Yu Chen; Jing-Shan Lu; Xu-Hui Li; Min Zhuo
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

Review 3.  Physiological roles of mammalian transmembrane adenylyl cyclase isoforms.

Authors:  Katrina F Ostrom; Justin E LaVigne; Tarsis F Brust; Roland Seifert; Carmen W Dessauer; Val J Watts; Rennolds S Ostrom
Journal:  Physiol Rev       Date:  2021-10-26       Impact factor: 37.312

4.  Evaluation of calcium-sensitive adenylyl cyclase AC1 and AC8 mRNA expression in the anterior cingulate cortex of mice with spared nerve injury neuropathy.

Authors:  Stephanie Shiers; Hajira Elahi; Stephanie Hennen; Theodore J Price
Journal:  Neurobiol Pain       Date:  2021-12-21

5.  Selective inhibition of adenylyl cyclase subtype 1 reduces inflammatory pain in chicken of gouty arthritis.

Authors:  Ren-Hao Liu; Wantong Shi; Yu-Xiang Zhang; Min Zhuo; Xu-Hui Li
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

Review 6.  Presynaptic long-term potentiation requires extracellular signal-regulated kinases in the anterior cingulate cortex.

Authors:  Qi-Yu Chen; Zhi-Ling Zhang; Qin Liu; Chao-Jun Chen; Xiao-Kang Zhang; Ping-Yi Xu; Min Zhuo
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

7.  FMRP acts as a key messenger for visceral pain modulation.

Authors:  Liu-Kun Yang; Liang Lu; Ban Feng; Xin-Shang Wang; Jiao Yue; Xu-Bo Li; Min Zhuo; Shui-Bing Liu
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.